MAINZ, Germany, & MAHWAH, N.J.--(BUSINESS WIRE)--SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems (NASDAQ: KRMD), a leading medical ...
Pharmaceutical Technology on MSN
Merus and Halozyme link on subcutaneous petosemtamab
Merus will pay Halozyme an upfront fee, milestone payments and low to mid single-digit royalties on net sales.
Merus N.V. and Halozyme Therapeutics Inc. have entered into a global non-exclusive collaboration and license agreement.
Merck & Co. has won European Commission approval of a formulation of its blockbuster cancer drug Keytruda that can be injected under the skin. The Rahway, N.J., drugmaker on Wednesday said the green ...
Merus N.V. (Nasdaq: MRUS) ("Merus"), an oncology company developing innovative, full-length multispecific antibodies and ...
CHICAGO--(BUSINESS WIRE)--Celltrion USA today announced the submission of a Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act (a “stand-alone” BLA) for ...
CINCINNATI, April 25, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® wearable drug delivery platform, announced ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Weekly ...
Halozyme to receive total upfront payment of $30 million for exclusive rights to targets The royalty rate for all products under the agreement is a tiered mid-single digit rate based on annual net ...
Lunsumio provides high rates of deep and long-lasting responses in third-line and later follicular lymphoma, a disease that ...
A new study published in the Journal of the European Academy of Dermatology and Venereology revealed that subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback